Hims & Hers boosts stock by partnering with Eli Lilly to offer GLP-1 drugs on its platform

Hims & Hers Health announced a partnership with Eli Lilly to offer Eli Lilly's GLP-1 drugs through its platform, providing a significant boost to the company's stock. This agreement is seen as a much-needed positive development for Hims & Hers, potentially expanding its product offerings and market reach. The collaboration could enhance the company's growth prospects by tapping into the growing demand for GLP-1 medications. Investors view this deal as a strategic move to strengthen Hims & Hers' position in the health sector.

Hims & Hers Health (HIMS) surged 8.69% to USD 26.15 on Pluang as of Nov 06, 2026 20:42 WIB, reflecting strong investor interest following its new partnership with Eli Lilly. Meanwhile, Eli Lilly (LLY) saw a slight dip of 1.22% to USD 1,350.96, with a market cap of $1.22 trillion. The deal appears to have energized HIMS trading, where 65% of orders were buys, contrasting with a more balanced 55% buy activity for LLY.